Back to Journals » OncoTargets and Therapy » Volume 10

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma

Authors Mao Y, Wu S

Received 26 January 2017

Accepted for publication 12 April 2017

Published 11 July 2017 Volume 2017:10 Pages 3399—3404

DOI https://doi.org/10.2147/OTT.S133349

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Yanjiao Mao, Shixiu Wu

Department of Radiotherapy Oncology, Hangzhou Cancer Hospital, Hangzhou, People’s Republic of China

Purpose: The purpose of this study was to explore the frequencies of ALK and ROS1 fusion genes in EGFR-mutant lung adenocarcinoma patients and examine the therapeutic efficacies of EGFR-tyrosine kinase inhibitors (TKIs).
Materials and methods: A total of 421 EGFR-mutated patients taking EGFR-TKIs were examined for ALK and ROS1 fusion genes based on reverse transcription-polymerase chain reaction (RT-PCR). Progression-free survival (PFS) and overall survival (OS) were evaluated by the Kaplan–Meier method and compared by the log-rank test.
Results: The mutations of ALK rearrangement (n=10) and ROS1 rearrangement (n=3) were detected. All the patients received EGFR-TKIs, and eight took subsequent ALK/ROS1 inhibitor. PFS was longer in single EGFR mutants (n=408) than in EGFR/ALK or EGFR/ROS1 counterparts (n=13; 10.7 vs 6.6 months, P=0.004). No difference in OS existed between single EGFR and EGFR/ALK or EGFR/ROS1 mutants (21.0 vs 23.0 months, P=0.196). The median PFS of eight patients treated with ALK/ROS1 inhibitor was 6.0 months.
Conclusion: Concomitant ALK/ROS1 fusion genes occurred in 3.1% EGFR-mutated lung adenocarcinoma patients. Concomitant ALK/ROS1–EGFR mutations may influence the therapeutic efficacy of EGFR-TKIs.

Keywords: epidermal growth factor receptor, ALK, ROS1, lung adenocarcinoma, efficacy
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Treatment and survival analyses of completely resected thymic carcinoma patients

Mao Y, Wu S

OncoTargets and Therapy 2015, 8:2503-2507

Published Date: 9 September 2015